- Analysis
- Barani Krishnan
- 32
Apex Healthcare Berhad, an investment holding company, engages in the development, manufacture, marketing, distribution, and wholesaling of pharmaceutical and healthcare products in Malaysia, Singapore, and internationally. It operates through three segments: Manufacturing, Distribution, and Corporate. The company offers a range of products, including cough mixture and antihistamine, anti-infective, anti-diabetic, anti-hypertensive, neuromuscular agent, analgesic, dermatological, and ophthalmological products in the form of tablets, capsules, oral liquids and suspensions, creams, and sterile eye drops under the Xepa brand name. It also engages in the contract manufacturing of surgical grade orthopedic devices, components, and surgical instruments, as well as orthopaedic components that are used in the surgical treatment of musculoskeletal disorders resulting from traumas, diseases, injuries, or deformities. In addition, the company is involved in the retail of pharmaceutical products; rental and management of properties; brand management activities; and provision of accounting and management consultancy services. The company offers its products under the XEPA, AVO, AVEX, AGNESIA, AEVA, HENNSON, REMECO, KAPS, and AVO DIAGNOSTICS brands through retail and e-commerce platforms. Apex Healthcare Berhad was founded in 1962 and is based in Malacca, Malaysia.
Metrics to compare | APER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPERPeersSector | |
---|---|---|---|---|
P/E Ratio | 20.7x | 16.4x | −0.6x | |
PEG Ratio | −0.26 | 0.32 | 0.00 | |
Price/Book | 2.2x | 2.0x | 2.6x | |
Price / LTM Sales | 1.8x | 1.9x | 3.1x | |
Upside (Analyst Target) | 16.7% | 11.8% | 48.2% | |
Fair Value Upside | Unlock | 15.0% | 8.0% | Unlock |